Esketamine and Quality of Life Improvement in Treatment-Resistant Depression Patients
Significant improvement in QoL was observed among patients with TRD treated with ESK-NS; ESK-NS in combination with an oral AD appears to offer meaningful benefit as a treatment option for patients with TRD who generally have substantial QoL and functioning limitations as a result of their depressive illness.
Authors
- Giovanni Martinotti
- Enrico Paolini (ORCID: https://orcid.org/0000-0001-6926-0255)
- Alessandro Gentile (ORCID: https://orcid.org/0000-0003-4839-489X)
- Stefano Marini (ORCID: https://orcid.org/0000-0002-1771-6940)
- Angelomarco Barioglio
- Matteo Lupi (ORCID: https://orcid.org/0000-0002-3183-0096)
- Alessandro Carano
- Domenico De Berardis (ORCID: https://orcid.org/0000-0003-4415-5058)
- T. Acciavatti (ORCID: https://orcid.org/0000-0001-6400-6995)
- Elicio Marinucci
- Marco Palmucci
- Monalisha Giri (ORCID: https://orcid.org/0009-0001-3040-7528)
Institutions
- Terre des Hommes (CH)
- University of Chieti-Pescara (IT)
- Marie Curie Hospice (GB)
- Agenzia Sanitaria Regionale Abruzzo (IT)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1097/jcp.0000000000002042
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00